New combination therapy for Plavix draws keen attention

Domestic pharmaceutical firms, Chong Kun Dang Pharmaceutical and Hanmi Pharmaceutical, have paid their keen attention to the ongoing regulatory screening for the new combination drug for Sanofi-Aventis’s Plavix.

Sources say Sanofi-Aventis submitted to the Korea Food and Drug Administration the results of Phase I study for the combination drug (clopidogrel + Aspirin). However, these data fail...